To the Editor: Chambers et al. (Oct. 3 issue)1 report birthoutcomes after prenatal exposure to fluoxetine but fail to provideresults for infants of mothers with mood disorders who werenot treated or who received other antidepressant drugs. Althoughtheir findings of similar rates of major malformations in fluoxetine-exposedinfants and unexposed infants are consistent with previous reports,2the findings of higher rates of perinatal complications afterthird-trimester exposure to fluoxetine are not.3
The authors propose that the occurrence of three minor malformationsin a single infant is a marker for embryonic disruption and,specifically, central nervous system disruption. . . . [Full Text of this Article]
References
This article has been cited by other articles:
Ferreira, E., Carceller, A. M., Agogue, C., Martin, B. Z., St-Andre, M., Francoeur, D., Berard, A.
(2007). Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates. Pediatrics
119: 52-59
[Abstract][Full Text]
Hemels, M. E., Einarson, A., Koren, G., Lanctot, K. L, Einarson, T. R
(2005). Antidepressant Use During Pregnancy and the Rates of Spontaneous Abortions: A Meta-Analysis. The Annals of Pharmacotherapy
39: 803-809
[Abstract][Full Text]
Costa, L. G., Steardo, L., Cuomo, V.
(2004). Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects. Pharmacol. Rev.
56: 103-147
[Abstract][Full Text]